Trends in Cardiovascular Medicine最新文献_第4页

Gender and Sex-related differences in Type 2 Myocardial Infarction: the undervalued side of a neglected disease. 2型心肌梗死的性别和性别相关差异：被忽视疾病的被低估的一面

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-07-21 DOI: 10.1016/j.tcm.2025.07.007

Francesco Angeli, Valentina Bucciarelli, Federica Moscucci, Susanna Sciomer, Fabrizio Ricci, Francesca Coppi, Luca Bergamaschi, Matteo Armillotta, Marcello Casuso Alvarez, Giulia Renda, Pasquale Perrone Filardi, Stefania Paolillo, Savina Nodari, Anna Vittoria Mattioli, Carmine Pizzi, Sabina Gallina

{"title":"Gender and Sex-related differences in Type 2 Myocardial Infarction: the undervalued side of a neglected disease.","authors":"Francesco Angeli, Valentina Bucciarelli, Federica Moscucci, Susanna Sciomer, Fabrizio Ricci, Francesca Coppi, Luca Bergamaschi, Matteo Armillotta, Marcello Casuso Alvarez, Giulia Renda, Pasquale Perrone Filardi, Stefania Paolillo, Savina Nodari, Anna Vittoria Mattioli, Carmine Pizzi, Sabina Gallina","doi":"10.1016/j.tcm.2025.07.007","DOIUrl":"10.1016/j.tcm.2025.07.007","url":null,"abstract":"Type 2 myocardial infarction (T2MI) occurs due to an imbalance between coronary blood supply and myocardial oxygen demand, leading to ischemia without the rupture of an atherosclerotic plaque, distinguishing it from Type 1 myocardial infarction (T1MI). Although T2MI is frequently diagnosed in clinical practice and associated with a poor prognosis, there is limited understanding of the sex differences in this condition, despite women representing a higher proportion of T2MI cases compared to T1MI. This review explores the definitions, epidemiological aspects, and clinical scenarios that reveal significant differences in T2MI between men and women that contribute to disparities in outcomes. It examines the unique roles that sex and gender play in the development, presentation, and diagnosis of T2MI, emphasizing the need for greater awareness of these factors. Understanding how these differences contribute to this condition is essential for developing patient-tailored approaches to managing this often-undervalued disease and improving outcomes.","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low density lipoprotein (LDL) and beyond in the treatment and prevention of cardiovascular disease. 低密度脂蛋白（LDL）及其以上在心血管疾病的治疗和预防中的作用。

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-07-19 DOI: 10.1016/j.tcm.2025.07.005

John Dunn, Charles H Hennekens

引用次数: 0

Inflammation and arrhythmias - the never-ending quest for actionable items. 炎症和心律失常-对可操作项目的永无止境的追求。

IF 9 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-07-17 DOI: 10.1016/j.tcm.2025.07.004

Alessio Gasperetti, Pasquale Santangeli

引用次数: 0

Pushing the limits of LDL cholesterol: Emerging paradigms in cardiovascular risk reduction. 推低密度脂蛋白胆固醇的极限：心血管风险降低的新范式。

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-07-13 DOI: 10.1016/j.tcm.2025.07.002

Dadmehr Yaghoubi, Tamer Sallam

{"title":"Pushing the limits of LDL cholesterol: Emerging paradigms in cardiovascular risk reduction.","authors":"Dadmehr Yaghoubi, Tamer Sallam","doi":"10.1016/j.tcm.2025.07.002","DOIUrl":"10.1016/j.tcm.2025.07.002","url":null,"abstract":"LDL cholesterol (LDL-C) has long been recognized as a primary contributor to cardiovascular disease. Over time, guideline-recommended LDL-C targets have varied considerably, trending toward progressively more aggressive therapeutic goals. The focus on residual risk reduction and development of novel therapies-including PCSK9 inhibitors, siRNA-based treatments, and ANGPTL3 inhibitors-have significantly expanded the options for achieving unprecedentedly low LDL-C levels. Given the fundamental role of cholesterol in cellular function, it has been long been postulated that very low cholesterol could be associated with adverse events. In this review, we dissect the benefits and potential risks of very low LDL-C levels. We begin by providing an overview of the evolution of LDL-C targets in previous guidelines and highlighting therapies-including newer agents-used for aggressive LDL-C lowering. Drawing on clinical and genetic evidence, we then examine the benefits and risks associated with achieving very low LDL-C levels. Finally, we present a practical framework for balancing the potential risks and benefits of intensive LDL-C reduction in patient care.","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials. 体位性站立性心动过速综合征治疗的证据：随机试验的系统回顾。

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-07-11 DOI: 10.1016/j.tcm.2025.07.001

Chun Shing Kwok, Soyoung Lee, Mark Hall, Adnan I Qureshi, Gregory Y H Lip, Yoon K Loke, Satish R Raj, Eric Holroyd

{"title":"The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials.","authors":"Chun Shing Kwok, Soyoung Lee, Mark Hall, Adnan I Qureshi, Gregory Y H Lip, Yoon K Loke, Satish R Raj, Eric Holroyd","doi":"10.1016/j.tcm.2025.07.001","DOIUrl":"10.1016/j.tcm.2025.07.001","url":null,"abstract":"Postural orthostatic tachycardia syndrome (POTS) is defined as the presence of chronic symptoms of orthostatic intolerance accompanied by an increase in heart rate greater than 30 beats per minute within 10 min of assuming an upright posture in the absences of orthostatic hypotension. It is a condition which lacks a definitive treatment strategy, with weak evidence and clinical expertise to support the available guidelines from the Heart Rhythm Society in 2015 and the Canadian Cardiovascular Society in 2020. The limited systematic reviews evaluating the treatment for POTS only reported three or fewer trials when many more trials have been published. In this systematic review, we evaluate the evidence for different treatments for POTS from 21 randomized clinical trials with 750 patients that took place between 2000 and 2023. This review summarizes the available evidence from trials on propranolol, midodrine, pyridostigmine and ivabradine as well as less commonly used medications such as desmopressin, melatonin, atomoxetine, modafinil, sertraline and intravenous immunoglobulins. Moreover, the trial evidence for non-pharmacological treatments is described including increase intake of dietary sodium, exercise training, compression and devices. We conclude that many small trials have evaluated different treatments for POTS. Large randomized trials are needed to determine if mainstay treatments beta-blockers, midodrine, and pyridostigmine should be used as first line treatment(s).","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single pill combination therapy for hypertension: New evidence and new challenges: Combination Therapy for Hypertension. 高血压单丸联合治疗：新证据和新挑战：高血压联合治疗。

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-07-01 DOI: 10.1016/j.tcm.2025.06.004

Martin Rosas-Peralta, Giuseppe Mancia, Miguel Camafort, Héctor Galván-Oseguera, Carlos M Ferrario, Luis Alcocer, Ernesto Cardona-Muñoz, Humberto Álvarez-López, Silvia Palomo-Piñón, Adolfo Chávez-Mendoza, Enrique Díaz-Díaz, José M Enciso-Muñoz

{"title":"Single pill combination therapy for hypertension: New evidence and new challenges: Combination Therapy for Hypertension.","authors":"Martin Rosas-Peralta, Giuseppe Mancia, Miguel Camafort, Héctor Galván-Oseguera, Carlos M Ferrario, Luis Alcocer, Ernesto Cardona-Muñoz, Humberto Álvarez-López, Silvia Palomo-Piñón, Adolfo Chávez-Mendoza, Enrique Díaz-Díaz, José M Enciso-Muñoz","doi":"10.1016/j.tcm.2025.06.004","DOIUrl":"10.1016/j.tcm.2025.06.004","url":null,"abstract":"Hypertension (HTN) continues to be one of the most important risk factors for major cardiovascular events and mortality. The global prevalence of hypertension is approximately 30% among adults over 20 years old. Cardiovascular risk stratification is crucial to determine the most appropriate pharmacological therapeutic strategy for hypertensive patients. Despite the many scales to stratify risk, none is perfect and represents weighted mathematical models to determine risk at 10 years. Reports have identified numerous limitations, and the challenge persists. A practical way to determine CV risk is the clinical approach based on 1) the number of risk factors, 2) the degree of elevation of blood pressure, 3) the presence of target organ damage/DM/CKD, and 4) a history of major cardiovascular events. Currently, it is recommended to start with dual therapy in a single pill (either ACE inhibitors or ARB2 + dihydropyridine calcium channel blockers or thiazide/thiazide-like diuretic); however, many patients could need to start with triple therapy (low or standard doses) if they belong to the high- or very high-risk group with elevation grade 2 or 3 of blood pressure. This article discusses this topic and establishes some practical recommendations for the physician of first contact.","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial commentary: Calcium modification techniques 钙改性技术。

IF 9 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-06-30 DOI: 10.1016/j.tcm.2025.06.006

James Cotton, Lampson Fan

引用次数: 0

Single pill combination therapy for hypertension management: Clinical benefits and considerations. 单片联合治疗高血压：临床益处和注意事项。

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-06-30 DOI: 10.1016/j.tcm.2025.06.007

Keisuke Narita

引用次数: 0

Acute myocardial infarction in patients without standard modifiable risk factors -A state-of-the-art review. 无标准可改变危险因素的急性心肌梗死患者的最新研究综述

IF 7.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-06-30 DOI: 10.1016/j.tcm.2025.06.005

Dimitrios V Moysidis, Andreas S Papazoglou, Vasileios Anastasiou, Stylianos Daios, Efstratios Karagiannidis, Barbara Fyntanidou, Vasileios Kamperidis, Matthaios Didagelos, George Giannakoulas, Antonios Ziakas, Georgios Giannopoulos, Vassilios Vassilikos

{"title":"Acute myocardial infarction in patients without standard modifiable risk factors -A state-of-the-art review.","authors":"Dimitrios V Moysidis, Andreas S Papazoglou, Vasileios Anastasiou, Stylianos Daios, Efstratios Karagiannidis, Barbara Fyntanidou, Vasileios Kamperidis, Matthaios Didagelos, George Giannakoulas, Antonios Ziakas, Georgios Giannopoulos, Vassilios Vassilikos","doi":"10.1016/j.tcm.2025.06.005","DOIUrl":"10.1016/j.tcm.2025.06.005","url":null,"abstract":"Acute myocardial infarction (AMI) in patients without standard modifiable risk factors (SMuRFs) is an increasingly recognized clinical entity. Traditionally, AMI has been closely associated with SMuRFs: hypertension, diabetes, dyslipidemia, and smoking. However, a subset of patients experience AMI without any of these established risk factors, posing diagnostic and therapeutic challenges. The true prevalence of AMI in SMuRF-less patients remains unclear, and the pathogenesis of coronary artery disease in these individuals is poorly understood. Current evidence suggests that unique mechanisms, including genetic predispositions and epigenetic modifications, inflammation, mental health and other non-traditional risk factors may contribute, though these remain to be clearly defined. Furthermore, the outcomes of SMuRF-less AMI present heterogeneity. In this review, we aim to examine the available literature on the underlying pathogenesis, potential causes of AMI in SMuRF-less patients, and their short- and long-term clinical outcomes compared to AMI patients with traditional risk factors. This knowledge could contribute to developing tailored treatment strategies and improving outcomes for this patient group.","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial commentary: Ventricular arrhythmias and older women 室性心律失常与老年妇女。

IF 9 2区医学

Trends in Cardiovascular Medicine Pub Date : 2025-06-29 DOI: 10.1016/j.tcm.2025.06.003

Nanette K. Wenger

引用次数: 0